## Kinga SaÅ,at

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7475084/publications.pdf

Version: 2024-02-01

236925 302126 2,021 91 25 39 citations h-index g-index papers 95 95 95 2840 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Phenylalanine-Based AMPA Receptor Antagonist as the Anticonvulsant Agent with Neuroprotective Activity—In Vitro and In Vivo Studies. Molecules, 2022, 27, 875.	3.8	4
2	Synthesis, anticonvulsant, and antinociceptive activity of new 3â€(3â€methylâ€2,5â€dioxoâ€3â€phenylpyrrolidinâ€1â€yl)propanamides and 3â€phenylâ€butanamides. Archi 2021, 354, e2000225.	v D <b>e</b> r1Phar	ma <b>∉</b> ie,
3	Wide-Range Measurement of Thermal Preference—A Novel Method for Detecting Analgesics Reducing Thermally-Evoked Pain in Mice. Molecules, 2021, 26, 612.	3.8	2
4	Serotonergic Neurotransmission System Modulator, Vortioxetine, and Dopaminergic D2/D3 Receptor Agonist, Ropinirole, Attenuate Fibromyalgia-Like Symptoms in Mice. Molecules, 2021, 26, 2398.	3.8	10
5	The Inclusion of Tolfenamic Acid into Cyclodextrins Stimulated by Microenvironmental pH Modification as a Way to Increase the Anti-Migraine Effect. Journal of Pain Research, 2021, Volume 14, 981-992.	2.0	5
6	Sex, Pramipexole and Tiagabine Affect Behavioral and Hormonal Response to Traumatic Stress in a Mouse Model of PTSD. Frontiers in Pharmacology, 2021, 12, 691598.	3.5	4
7	Antiepileptic Drug Tiagabine Does Not Directly Target Key Cardiac Ion Channels Kv11.1, Nav1.5 and Cav1.2. Molecules, 2021, 26, 3522.	3.8	4
8	The Microglial Activation Inhibitor Minocycline, Used Alone and in Combination with Duloxetine, Attenuates Pain Caused by Oxaliplatin in Mice. Molecules, 2021, 26, 3577.	3.8	12
9	Novel Functionalized Amino Acids as Inhibitors of GABA Transporters with Analgesic Activity. ACS Chemical Neuroscience, 2021, 12, 3073-3100.	3.5	6
10	Development of tricyclic N-benzyl-4-hydroxybutanamide derivatives as inhibitors of GABA transporters mGAT1-4 with anticonvulsant, antinociceptive, and antidepressant activity. European Journal of Medicinal Chemistry, 2021, 221, 113512.	5 <b>.</b> 5	6
11	Development and crystallography-aided SAR studies of multifunctional BuChE inhibitors and 5-HT6R antagonists with $\hat{I}^2$ -amyloid anti-aggregation properties. European Journal of Medicinal Chemistry, 2021, 225, 113792.	5.5	13
12	Novel mouse GABA uptake inhibitors with enhanced inhibitory activity toward mGAT3/4 and their effect on pain threshold in mice. European Journal of Medicinal Chemistry, 2020, 188, 111920.	5 <b>.</b> 5	11
13	Behavioral effects of buspirone in a mouse model of posttraumatic stress disorder. Behavioural Brain Research, 2020, 381, 112380.	2.2	1
14	Structure-activity relationship study of tryptophan-based butyrylcholinesterase inhibitors. European Journal of Medicinal Chemistry, 2020, 208, 112766.	5.5	17
15	Chemotherapy-induced peripheral neuropathy: part $1\hat{a}\in$ "current state of knowledge and perspectives for pharmacotherapy. Pharmacological Reports, 2020, 72, 486-507.	3.3	68
16	Anticonvulsant and analgesic in neuropathic pain activity in a group of new aminoalkanol derivatives. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127325.	2.2	4
17	Chemotherapy-induced peripheral neuropathy—part 2: focus on the prevention of oxaliplatin-induced neurotoxicity. Pharmacological Reports, 2020, 72, 508-527.	3.3	66
18	Comparison of Bromhexine and its Active Metabolite - Ambroxol as Potential Analgesics Reducing Oxaliplatin-induced Neuropathic Pain - Pharmacodynamic and Molecular Docking Studies. Current Drug Metabolism, 2020, 21, 548-561.	1.2	10

#	Article	IF	Citations
19	KM-416, a novel phenoxyalkylaminoalkanol derivative with anticonvulsant properties exerts analgesic, local anesthetic, and antidepressant-like activities. Pharmacodynamic, pharmacokinetic, and forced degradation studies. European Journal of Pharmacology, 2020, 886, 173540.	3.5	5
20	Search for multifunctional agents against Alzheimer's disease among non-imidazole histamine H3 receptor ligands. In vitro and in vivo pharmacological evaluation and computational studies of piperazine derivatives. Bioorganic Chemistry, 2019, 90, 103084.	4.1	13
21	Synthesis and pharmacological evaluation of novel N-Mannich bases derived from 5,5-diphenyl and 5,5-di(propan-2-yl)imidazolidine-2,4-dione core. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2387-2392.	2.2	5
22	Dopamine D2/D3 receptor agonists attenuate PTSD-like symptoms in mice exposed to single prolonged stress. Neuropharmacology, 2019, 155, 1-9.	4.1	17
23	Searching for analgesic drug candidates alleviating oxaliplatinâ€induced cold hypersensitivity in mice. Chemical Biology and Drug Design, 2019, 93, 1061-1072.	3.2	15
24	Recent advances in the neurobiology of posttraumatic stress disorder: A review of possible mechanisms underlying an effective pharmacotherapy. Pharmacological Research, 2019, 142, 30-49.	7.1	23
25	Studies on the Activity of Selected Highly Lipophilic Compounds toward hGAT1 Inhibition. Part II. ACS Chemical Neuroscience, 2019, 10, 337-347.	3.5	7
26	Interventional and preventive effects of aripiprazole and ceftriaxone used alone or in combination on oxaliplatin-induced tactile and cold allodynia in mice. Biomedicine and Pharmacotherapy, 2019, 111, 882-890.	5.6	14
27	Phencyclidine and Scopolamine for Modeling Amnesia in Rodents: Direct Comparison with the Use of Barnes Maze Test and Contextual Fear Conditioning Test in Mice. Neurotoxicity Research, 2018, 34, 431-441.	2.7	16
28	Effect of selected drugs on zinc accumulation in teeth of laboratory animals. Pharmacological Reports, 2018, 70, 684-687.	3.3	2
29	Evaluation of cebranopadol, a dually acting nociceptin/orphanin FQ and opioid receptor agonist in mouse models of acute, tonic, and chemotherapy-induced neuropathic pain. Inflammopharmacology, 2018, 26, 361-374.	3.9	25
30	The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity. Journal of Medicinal Chemistry, 2018, 61, 119-139.	6.4	112
31	Enhanced pharmacological efficacy of sumatriptan due to modification of its physicochemical properties by inclusion in selected cyclodextrins. Scientific Reports, 2018, 8, 16184.	<b>3.</b> 3	15
32	Docking and pharmacodynamic studies on hGAT1 inhibition activity in the presence of selected neuronal and astrocytic inhibitors. Part I. Journal of Molecular Graphics and Modelling, 2018, 85, 171-181.	2.4	6
33	Novel amide derivatives of 1,3-dimethyl-2,6-dioxopurin-7-yl-alkylcarboxylic acids as multifunctional TRPA1 antagonists and PDE4/7 inhibitors: A new approach for the treatment of pain. European Journal of Medicinal Chemistry, 2018, 158, 517-533.	5 <b>.</b> 5	27
34	Time-shifted co-administration of sub-analgesic doses of ambroxol and pregabalin attenuates oxaliplatin-induced cold allodynia in mice. Biomedicine and Pharmacotherapy, 2018, 106, 930-940.	5.6	19
35	Thiazoles with cyclopropyl fragment as antifungal, anticonvulsant, and anti-Toxoplasma gondii agents: synthesis, toxicity evaluation, and molecular docking study. Medicinal Chemistry Research, 2018, 27, 2125-2140.	2.4	28
36	Synthesis and activity of di- or trisubstituted N -(phenoxyalkyl)- or N -{2-[2-(phenoxy)ethoxy]ethyl}piperazine derivatives on the central nervous system. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2039-2049.	2.2	7

#	Article	IF	CITATIONS
37	The potential antidepressant action and adverse effects profile of scopolamine co-administered with the mGlu7 receptor allosteric agonist AMN082 in mice. Neuropharmacology, 2018, 141, 214-222.	4.1	16
38	Acute cold allodynia induced by oxaliplatin is attenuated by amitriptyline. Acta Neurobiologiae Experimentalis, 2018, 78, 315-321.	0.7	10
39	Experimental Drugs for Neuropathic Pain. Current Neuropharmacology, 2018, 16, 1193-1209.	2.9	20
40	Acute cold allodynia induced by oxaliplatin is attenuated by amitriptyline. Acta Neurobiologiae Experimentalis, 2018, 78, 315-321.	0.7	3
41	Comparison of pro-amnesic efficacy of scopolamine, biperiden, and phencyclidine by using passive avoidance task in CD-1 mice. Journal of Pharmacological and Toxicological Methods, 2017, 86, 76-80.	0.7	13
42	Comparison of the Psychopharmacological Effects of Tiletamine and Ketamine in Rodents. Neurotoxicity Research, 2017, 32, 544-554.	2.7	22
43	Effect of pregabalin on fear-based conditioned avoidance learning and spatial learning in a mouse model of scopolamine-induced amnesia. Toxicology Mechanisms and Methods, 2017, 27, 181-190.	2.7	5
44	Antinociceptive, antiallodynic and antihyperalgesic effects of the 5-HT1A receptor selective agonist, NLX-112 in mouse models of pain. Neuropharmacology, 2017, 125, 181-188.	4.1	35
45	Antidepressant-like activity of venlafaxine and clonidine in mice exposed to single prolonged stress – A model of post-traumatic stress disorder. Pharmacodynamic and molecular docking studies. Brain Research, 2017, 1673, 1-10.	2.2	14
46	Potential role of selected antiepileptics used in neuropathic pain as human GABA transporter isoform 1 (GAT1) inhibitors—Molecular docking and pharmacodynamic studies. European Journal of Pharmaceutical Sciences, 2017, 96, 362-372.	4.0	19
47	Novel, highly potent and inÂvivo active inhibitor of GABA transporter subtype 1 with anticonvulsant, anxiolytic, antidepressant and antinociceptive properties. Neuropharmacology, 2017, 113, 331-342.	4.1	33
48	Search for new potential anticonvulsants with anxiolytic and antidepressant properties among derivatives of 4,4-diphenylpyrrolidin-2-one. Pharmacological Reports, 2017, 69, 105-111.	3.3	5
49	Synthesis, biological evaluation and molecular docking studies of novel quinuclidinone derivatives as potential antimicrobial and anticonvulsant agents. Medicinal Chemistry Research, 2017, 26, 2088-2104.	2.4	7
50	Development of an in-vivo active reversible butyrylcholinesterase inhibitor. Scientific Reports, 2016, 6, 39495.	3.3	105
51	Anticonvulsant and antinociceptive activity of new amides derived from 3-phenyl-2,5-dioxo-pyrrolidine-1-yl-acetic acid in mice. European Journal of Pharmacology, 2016, 781, 239-249.	3.5	22
52	Synthesis, antimicrobial and anticonvulsant screening of small library of tetrahydro-2H-thiopyran-4-yl based thiazoles and selenazoles. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 24-39.	5.2	28
53	Synthesis and anticonvulsant activities of novel 2-(cyclopentylmethylene)hydrazinyl-1,3-thiazoles in mouse models of seizures. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 1576-1582.	<b>5.</b> 2	25
54	Antidepressant-like effects of scopolamine in mice are enhanced by the group II mGlu receptor antagonist LY341495. Neuropharmacology, 2016, 111, 169-179.	4.1	31

#	Article	IF	Citations
55	Evaluation of anticonvulsant and antinociceptive properties of new N-Mannich bases derived from pyrrolidine-2,5-dione and 3-methylpyrrolidine-2,5-dione. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 339-348.	3.0	20
56	Effect of pregabalin on contextual memory deficits and inflammatory state-related protein expression in streptozotocin-induced diabetic mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 613-623.	3.0	20
57	Antinociceptive activity of novel amide derivatives of imidazolidine-2,4-dione in a mouse model of acute pain. Pharmacological Reports, 2016, 68, 529-535.	3.3	7
58	Synthesis, and anticonvulsant activity of new amides derived from 3-methyl- or 3-ethyl-3-methyl-2,5-dioxo-pyrrolidin-1-yl-acetic acids. Bioorganic and Medicinal Chemistry, 2016, 24, 1598-1607.	3.0	25
59	The anxiolytic-like activity of a novel N-cycloalkyl-N-benzoylpiperazine derivative. Pharmacological Reports, 2016, 68, 62-65.	3.3	2
60	Antinociceptive activity of transient receptor potential channel TRPV1, TRPA1, and TRPM8 antagonists in neurogenic and neuropathic pain models in mice. Journal of Zhejiang University: Science B, 2015, 16, 167-178.	2.8	65
61	Antinociceptive properties of N-Mannich bases derived from 3-substituted pyrrolidine-2,5-dione in the formalin model of persistent pain in mice. Pharmacological Reports, 2015, 67, 63-68.	3.3	14
62	Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: Role of activity at NMDA receptor. Neuropharmacology, 2015, 99, 301-307.	4.1	61
63	3-[4-(3-Trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one and pregabalin attenuate tactile allodynia in the mouse model of chronic constriction injury. Toxicology Mechanisms and Methods, 2015, 25, 514-523.	2.7	5
64	Modeling analgesic drug interactions using support vector regression: A new approach to isobolographic analysis. Journal of Pharmacological and Toxicological Methods, 2015, 71, 95-102.	0.7	7
65	Cebranopadol: a first-in-class potent analgesic agent with agonistic activity at nociceptin/orphanin FQ and opioid receptors. Expert Opinion on Investigational Drugs, 2015, 24, 837-844.	4.1	18
66	Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with $\hat{l}^2$ -amyloid anti-aggregation properties and beneficial effects on memory in vivo. Bioorganic and Medicinal Chemistry, 2015, 23, 2445-2457.	3.0	42
67	The effect of GABA transporter 1 (GAT1) inhibitor, tiagabine, on scopolamine-induced memory impairments in mice. Pharmacological Reports, 2015, 67, 1155-1162.	3.3	37
68	Anticonvulsant active inhibitor of GABA transporter subtype 1, tiagabine, with activity in mouse models of anxiety, pain and depression. Pharmacological Reports, 2015, 67, 465-472.	3.3	55
69	An Overview of the Pharmacological Properties and Potential Applications of Natural Monoterpenes. Mini-Reviews in Medicinal Chemistry, 2015, 14, 1156-1168.	2.4	134
70	Influence of analgesic active 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one on the antioxidant status, glucose utilization and lipid accumulation in somein vitroandex vivoassays. Toxicology Mechanisms and Methods, 2014, 24, 204-211.	2.7	3
71	Antiallodynic and antihyperalgesic activity of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one compared to pregabalin in chemotherapy-induced neuropathic pain in mice. Pharmacology Biochemistry and Behavior, 2014, 122, 173-181.	2.9	55
72	Synthesis, biological evaluation and structure–activity relationship of new GABA uptake inhibitors, derivatives of 4-aminobutanamides. European Journal of Medicinal Chemistry, 2014, 83, 256-273.	5.5	17

#	Article	IF	CITATIONS
73	Zucapsaicin for the treatment of neuropathic pain. Expert Opinion on Investigational Drugs, 2014, 23, 1433-1440.	4.1	24
74	New investigational drugs for the treatment of neuropathic pain. Expert Opinion on Investigational Drugs, 2014, 23, 1093-1104.	4.1	37
75	Evaluation of antinociceptive and antioxidant properties of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one in mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386, 493-505.	3.0	34
76	Nitrogen, Oxygen or Sulfur Containing Heterocyclic Compounds as Analgesic Drugs Used as Modulators of the Nitroxidative Stress. Mini-Reviews in Medicinal Chemistry, 2013, 13, 335-352.	2.4	3
77	2-Substituted 4-hydroxybutanamides as potential inhibitors of γ-aminobutyric acid transporters mGAT1–mGAT4: Synthesis and biological evaluation. Bioorganic and Medicinal Chemistry, 2013, 21, 5154-5167.	3.0	14
78	The application of support vector regression for prediction of the antiallodynic effect of drug combinations in the mouse model of streptozocin-induced diabetic neuropathy. Computer Methods and Programs in Biomedicine, 2013, 111, 330-337.	4.7	22
79	Evaluation of anxiolytic-like, anticonvulsant, antidepressant-like and antinociceptive properties of new 2-substituted 4-hydroxybutanamides with affinity for GABA transporters in mice. Pharmacology Biochemistry and Behavior, 2013, 110, 145-153.	2.9	26
80	Evaluation of analgesic, antioxidant, cytotoxic and metabolic effects of pregabalin for the use in neuropathic pain. Neurological Research, 2013, 35, 948-958.	1.3	16
81	Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain. Current Medicinal Chemistry, 2013, 20, 1409-1436.	2.4	46
82	Nitrogen, oxygen or sulfur containing heterocyclic compounds as analgesic drugs used as modulators of the nitroxidative stress. Mini-Reviews in Medicinal Chemistry, 2013, 13, 335-52.	2.4	25
83	Analgesic, antioedematous and antioxidant activity of $\hat{I}^3$ -butyrolactone derivatives in rodents. Behavioural Pharmacology, 2012, 23, 407-416.	1.7	16
84	Search for anticonvulsant and analgesic active derivatives of dihydrofuran-2(3H)-one. Bioorganic and Medicinal Chemistry, 2012, 20, 6533-6544.	3.0	12
85	Synthesis and pharmacological properties of new GABA uptake inhibitors. Pharmacological Reports, 2012, 64, 817-833.	3.3	22
86	New approach to predicting proconvulsant activity with the use of Support Vector Regression. Computers in Biology and Medicine, 2012, 42, 575-581.	7.0	7
87	Analgesic and anticonvulsant activity of new derivatives of 2-substituted 4-hydroxybutanamides in mice. Pharmacological Reports, 2012, 64, 102-112.	3.3	15
88	Analgesic, anticonvulsant and antioxidant activities of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one dihydrochloride in mice. Pharmacology Biochemistry and Behavior, 2012, 101, 138-147.	2.9	29
89	GABA transporters as targets for new drugs. Future Medicinal Chemistry, 2011, 3, 211-222.	2.3	46
90	Analgesic activity of 3-mono-substituted derivatives of dihydrofuran-2-one in experimental rodent models of pain. Pharmacological Reports, 2009, 61, 807-818.	3.3	21

#	Article	IF	CITATIONS
91	Influence of new gamma-hydroxybutyric acid amide analogues on the central nervous system activity in mice. Polish Journal of Pharmacology, 2002, 54, 731-6.	0.3	3